Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

Nijenhuis VJ, Stella PR, Baan J, Brueren BR, de Jaegere PP, den Heijer P, Hofma SH, Kievit P, Slagboom T, van den Heuvel AF, van der Kley F, van Garsse L, van Houwelingen KG, Van't Hof AW, Ten Berg JM.
PMID: 24287807
Neth Heart J. 2014 Feb;22(2):64-9. doi: 10.1007/s12471-013-0496-6.

PURPOSE: To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI).METHODS: For every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin,...

Cite
Nijenhuis VJ, Stella PR, Baan J, et al. Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals. Neth Heart J. 2014;22(2):64-9doi: 10.1007/s12471-013-0496-6.
Nijenhuis, V. J., Stella, P. R., Baan, J., Brueren, B. R., de Jaegere, P. P., den Heijer, P., Hofma, S. H., Kievit, P., Slagboom, T., van den Heuvel, A. F., van der Kley, F., van Garsse, L., van Houwelingen, K. G., Van't Hof, A. W., & Ten Berg, J. M. (2014). Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 22(2), 64-9. https://doi.org/10.1007/s12471-013-0496-6
Nijenhuis, V J, et al. "Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 22,2 (2014): 64-9. doi: https://doi.org/10.1007/s12471-013-0496-6
Nijenhuis VJ, Stella PR, Baan J, Brueren BR, de Jaegere PP, den Heijer P, Hofma SH, Kievit P, Slagboom T, van den Heuvel AF, van der Kley F, van Garsse L, van Houwelingen KG, Van't Hof AW, Ten Berg JM. Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals. Neth Heart J. 2014 Feb;22(2):64-9. doi: 10.1007/s12471-013-0496-6. PMID: 24287807; PMCID: PMC3967563.
Copy Download .nbib Format: NLM
The impact of peroxisomes on cellular aging and death.

Frontiers in oncology

Manivannan S, Scheckhuber CQ, Veenhuis M, van der Klei IJ.
PMID: 22662318
Front Oncol. 2012 May 21;2:50. doi: 10.3389/fonc.2012.00050. eCollection 2012.

Peroxisomes are ubiquitous eukaryotic organelles, which perform a plethora of functions including hydrogen peroxide metabolism and β-oxidation of fatty acids. Reactive oxygen species produced by peroxisomes are a major contributing factor to cellular oxidative stress, which is supposed to...

Cite
Manivannan S, Scheckhuber CQ, Veenhuis M, et al. The impact of peroxisomes on cellular aging and death. Front Oncol. 2012;2:50doi: 10.3389/fonc.2012.00050.
Manivannan, S., Scheckhuber, C. Q., Veenhuis, M., & van der Klei, I. J. (2012). The impact of peroxisomes on cellular aging and death. Frontiers in oncology, 250. https://doi.org/10.3389/fonc.2012.00050
Manivannan, Selvambigai, et al. "The impact of peroxisomes on cellular aging and death." Frontiers in oncology vol. 2 (2012): 50. doi: https://doi.org/10.3389/fonc.2012.00050
Manivannan S, Scheckhuber CQ, Veenhuis M, van der Klei IJ. The impact of peroxisomes on cellular aging and death. Front Oncol. 2012 May 21;2:50. doi: 10.3389/fonc.2012.00050. eCollection 2012. PMID: 22662318; PMCID: PMC3356858.
Copy Download .nbib Format: NLM
Extra-hepatic Acromegaly.

European endocrinology

Franck SE, van der Lely AJ, Neggers S.
PMID: 30349613
Eur Endocrinol. 2013 Mar;9(1):66-70. doi: 10.17925/EE.2013.09.01.66. Epub 2013 Mar 15.

After the introduction of somatostatin analogs (LA-SMSA) and the growth hormone (GH) receptor antagonist, pegvisomant (Peg-v) normal serum insulin-like growth factor-1 (IGF-1) concentrations in virtually every patients with acromegaly is possible. The impact of these products on the GH-IGF1...

Cite
Franck SE, van der Lely AJ, Neggers S. Extra-hepatic Acromegaly. Eur Endocrinol. 2013;9(1):66-70doi: 10.17925/EE.2013.09.01.66.
Franck, S. E., van der Lely, A. J., & Neggers, S. (2013). Extra-hepatic Acromegaly. European endocrinology, 9(1), 66-70. https://doi.org/10.17925/EE.2013.09.01.66
Franck, Sanne E, et al. "Extra-hepatic Acromegaly." European endocrinology vol. 9,1 (2013): 66-70. doi: https://doi.org/10.17925/EE.2013.09.01.66
Franck SE, van der Lely AJ, Neggers S. Extra-hepatic Acromegaly. Eur Endocrinol. 2013 Mar;9(1):66-70. doi: 10.17925/EE.2013.09.01.66. Epub 2013 Mar 15. PMID: 30349613; PMCID: PMC6193516.
Copy Download .nbib Format: NLM
Towards an Earlier Diagnosis of Acromegaly and Gigantism.

Journal of clinical medicine

Sisco J, van der Lely AJ.
PMID: 33810319
J Clin Med. 2021 Mar 26;10(7). doi: 10.3390/jcm10071363.

Acromegaly is a rare disease and the clinical features of acromegaly develop insidiously; its diagnosis is often significantly delayed. Therefore, earlier diagnosis will improve the quality of life of the patient and reduce the need for other therapies to...

Cite
Sisco J, van der Lely AJ. Towards an Earlier Diagnosis of Acromegaly and Gigantism. J Clin Med. 2021;10(7)doi: 10.3390/jcm10071363.
Sisco, J., & van der Lely, A. J. (2021). Towards an Earlier Diagnosis of Acromegaly and Gigantism. Journal of clinical medicine, 10(7), . https://doi.org/10.3390/jcm10071363
Sisco, Jill, and van der Lely, A J. "Towards an Earlier Diagnosis of Acromegaly and Gigantism." Journal of clinical medicine vol. 10,7 (2021). doi: https://doi.org/10.3390/jcm10071363
Sisco J, van der Lely AJ. Towards an Earlier Diagnosis of Acromegaly and Gigantism. J Clin Med. 2021 Mar 26;10(7). doi: 10.3390/jcm10071363. PMID: 33810319; PMCID: PMC8036484.
Copy Download .nbib Format: NLM
Thyroid Function in Adults with Prader-Willi Syndrome; a Cohort Study and Literature Review.

Journal of clinical medicine

Pellikaan K, Snijders F, Rosenberg AGW, Davidse K, van den Berg SAA, Visser WE, van der Lely AJ, de Graaff LCG.
PMID: 34501256
J Clin Med. 2021 Aug 25;10(17). doi: 10.3390/jcm10173804.

Prader-Willi syndrome (PWS) is a complex genetic syndrome combining hypotonia, hyperphagia, a PWS-specific neurocognitive phenotype, and pituitary hormone deficiencies, including hypothyroidism. The low muscle mass associated with PWS causes a low energy expenditure due to a low basal metabolic...

Cite
Pellikaan K, Snijders F, Rosenberg AGW, et al. Thyroid Function in Adults with Prader-Willi Syndrome; a Cohort Study and Literature Review. J Clin Med. 2021;10(17)doi: 10.3390/jcm10173804.
Pellikaan, K., Snijders, F., Rosenberg, A. G. W., Davidse, K., van den Berg, S. A. A., Visser, W. E., van der Lely, A. J., & de Graaff, L. C. G. (2021). Thyroid Function in Adults with Prader-Willi Syndrome; a Cohort Study and Literature Review. Journal of clinical medicine, 10(17), . https://doi.org/10.3390/jcm10173804
Pellikaan, Karlijn, et al. "Thyroid Function in Adults with Prader-Willi Syndrome; a Cohort Study and Literature Review." Journal of clinical medicine vol. 10,17 (2021). doi: https://doi.org/10.3390/jcm10173804
Pellikaan K, Snijders F, Rosenberg AGW, Davidse K, van den Berg SAA, Visser WE, van der Lely AJ, de Graaff LCG. Thyroid Function in Adults with Prader-Willi Syndrome; a Cohort Study and Literature Review. J Clin Med. 2021 Aug 25;10(17). doi: 10.3390/jcm10173804. PMID: 34501256; PMCID: PMC8432005.
Copy Download .nbib Format: NLM
What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of 'Internal Medicine for Rare Genetic Syndromes'.

Journal of clinical medicine

Rosenberg AGW, Pater MRA, Pellikaan K, Davidse K, Kattentidt-Mouravieva AA, Kersseboom R, Bos-Roubos AG, van Eeghen A, Veen JMC, van der Meulen JJ, van Aalst-van Wieringen N, Hoekstra FME, van der Lely AJ, de Graaff LCG.
PMID: 34830739
J Clin Med. 2021 Nov 22;10(22). doi: 10.3390/jcm10225457.

Patients with complex rare genetic syndromes (CRGS) have combined medical problems affecting multiple organ systems. Pediatric multidisciplinary (MD) care has improved life expectancy, however, transfer to internal medicine is hindered by the lack of adequate MD care for adults....

Cite
Rosenberg AGW, Pater MRA, Pellikaan K, et al. What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of 'Internal Medicine for Rare Genetic Syndromes'. J Clin Med. 2021;10(22)doi: 10.3390/jcm10225457.
Rosenberg, A. G. W., Pater, M. R. A., Pellikaan, K., Davidse, K., Kattentidt-Mouravieva, A. A., Kersseboom, R., Bos-Roubos, A. G., van Eeghen, A., Veen, J. M. C., van der Meulen, J. J., van Aalst-van Wieringen, N., Hoekstra, F. M. E., van der Lely, A. J., & de Graaff, L. C. G. (2021). What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of 'Internal Medicine for Rare Genetic Syndromes'. Journal of clinical medicine, 10(22), . https://doi.org/10.3390/jcm10225457
Rosenberg, Anna G W, et al. "What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of 'Internal Medicine for Rare Genetic Syndromes'." Journal of clinical medicine vol. 10,22 (2021). doi: https://doi.org/10.3390/jcm10225457
Rosenberg AGW, Pater MRA, Pellikaan K, Davidse K, Kattentidt-Mouravieva AA, Kersseboom R, Bos-Roubos AG, van Eeghen A, Veen JMC, van der Meulen JJ, van Aalst-van Wieringen N, Hoekstra FME, van der Lely AJ, de Graaff LCG. What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of 'Internal Medicine for Rare Genetic Syndromes'. J Clin Med. 2021 Nov 22;10(22). doi: 10.3390/jcm10225457. PMID: 34830739; PMCID: PMC8622899.
Copy Download .nbib Format: NLM
Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states.

Diabetology & metabolic syndrome

Özcan B, Leenen PJM, Delhanty PJD, Baldéon-Rojas LY, Neggers SJ, van der Lely AJ.
PMID: 28572856
Diabetol Metab Syndr. 2017 May 31;9:43. doi: 10.1186/s13098-017-0239-8. eCollection 2017.

BACKGROUND: Type 2 diabetes (T2D) is associated with reduced numbers and impaired function of circulating angiogenic cells (CAC) which contributes to the progression of atherosclerosis and microvascular disease. Previous studies suggest that short-term infusion of unacylated ghrelin (UAG) normalizes...

Cite
Özcan B, Leenen PJM, Delhanty PJD, et al. Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states. Diabetol Metab Syndr. 2017;9:43doi: 10.1186/s13098-017-0239-8.
Özcan, B., Leenen, P. J. M., Delhanty, P. J. D., Baldéon-Rojas, L. Y., Neggers, S. J., & van der Lely, A. J. (2017). Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states. Diabetology & metabolic syndrome, 943. https://doi.org/10.1186/s13098-017-0239-8
Özcan, Behiye, et al. "Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states." Diabetology & metabolic syndrome vol. 9 (2017): 43. doi: https://doi.org/10.1186/s13098-017-0239-8
Özcan B, Leenen PJM, Delhanty PJD, Baldéon-Rojas LY, Neggers SJ, van der Lely AJ. Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states. Diabetol Metab Syndr. 2017 May 31;9:43. doi: 10.1186/s13098-017-0239-8. eCollection 2017. PMID: 28572856; PMCID: PMC5452348.
Copy Download .nbib Format: NLM
Ghrelin.

Molecular metabolism

Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, D'Alessio D, Depoortere I, Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S, Dickson SL, Diéguez C, Granata R, Grill HJ, Grove K, Habegger KM, Heppner K, Heiman ML, Holsen L, Holst B, Inui A, Jansson JO, Kirchner H, Korbonits M, Laferrère B, LeRoux CW, Lopez M, Morin S, Nakazato M, Nass R, Perez-Tilve D, Pfluger PT, Schwartz TW, Seeley RJ, Sleeman M, Sun Y, Sussel L, Tong J, Thorner MO, van der Lely AJ, van der Ploeg LH, Zigman JM, Kojima M, Kangawa K, Smith RG, Horvath T, Tschöp MH.
PMID: 26042199
Mol Metab. 2015 Mar 21;4(6):437-60. doi: 10.1016/j.molmet.2015.03.005. eCollection 2015 Jun.

BACKGROUND: The gastrointestinal peptide hormone ghrelin was discovered in 1999 as the endogenous ligand of the growth hormone secretagogue receptor. Increasing evidence supports more complicated and nuanced roles for the hormone, which go beyond the regulation of systemic energy...

Cite
Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab. 2015;4(6):437-60doi: 10.1016/j.molmet.2015.03.005.
Müller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., Casanueva, F. F., D'Alessio, D., Depoortere, I., Geliebter, A., Ghigo, E., Cole, P. A., Cowley, M., Cummings, D. E., Dagher, A., Diano, S., Dickson, S. L., Diéguez, C., Granata, R., Grill, H. J., Grove, K., Habegger, K. M., Heppner, K., Heiman, M. L., Holsen, L., Holst, B., Inui, A., Jansson, J. O., Kirchner, H., Korbonits, M., Laferrère, B., LeRoux, C. W., Lopez, M., Morin, S., Nakazato, M., Nass, R., Perez-Tilve, D., Pfluger, P. T., Schwartz, T. W., Seeley, R. J., Sleeman, M., Sun, Y., Sussel, L., Tong, J., Thorner, M. O., van der Lely, A. J., van der Ploeg, L. H., Zigman, J. M., Kojima, M., Kangawa, K., Smith, R. G., Horvath, T., & Tschöp, M. H. (2015). Ghrelin. Molecular metabolism, 4(6), 437-60. https://doi.org/10.1016/j.molmet.2015.03.005
Müller, T D, et al. "Ghrelin." Molecular metabolism vol. 4,6 (2015): 437-60. doi: https://doi.org/10.1016/j.molmet.2015.03.005
Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, D'Alessio D, Depoortere I, Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S, Dickson SL, Diéguez C, Granata R, Grill HJ, Grove K, Habegger KM, Heppner K, Heiman ML, Holsen L, Holst B, Inui A, Jansson JO, Kirchner H, Korbonits M, Laferrère B, LeRoux CW, Lopez M, Morin S, Nakazato M, Nass R, Perez-Tilve D, Pfluger PT, Schwartz TW, Seeley RJ, Sleeman M, Sun Y, Sussel L, Tong J, Thorner MO, van der Lely AJ, van der Ploeg LH, Zigman JM, Kojima M, Kangawa K, Smith RG, Horvath T, Tschöp MH. Ghrelin. Mol Metab. 2015 Mar 21;4(6):437-60. doi: 10.1016/j.molmet.2015.03.005. eCollection 2015 Jun. PMID: 26042199; PMCID: PMC4443295.
Copy Download .nbib Format: NLM
Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data.

European heart journal

Kamperidis V, van Rosendael PJ, Katsanos S, van der Kley F, Regeer M, Al Amri I, Sianos G, Marsan NA, Delgado V, Bax JJ.
PMID: 26033985
Eur Heart J. 2015 Aug 14;36(31):2087-2096. doi: 10.1093/eurheartj/ehv188. Epub 2015 Jun 01.

AIMS: Low gradient severe aortic stenosis (AS) with preserved left ventricular ejection fraction (LVEF) may be attributed to aortic valve area index (AVAi) underestimation due to the assumption of a circular shape of the left ventricular outflow tract (LVOT)...

Cite
Kamperidis V, van Rosendael PJ, Katsanos S, et al. Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data. Eur Heart J. 2015;36(31):2087-2096doi: 10.1093/eurheartj/ehv188.
Kamperidis, V., van Rosendael, P. J., Katsanos, S., van der Kley, F., Regeer, M., Al Amri, I., Sianos, G., Marsan, N. A., Delgado, V., & Bax, J. J. (2015). Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data. European heart journal, 36(31), 2087-2096. https://doi.org/10.1093/eurheartj/ehv188
Kamperidis, Vasileios, et al. "Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data." European heart journal vol. 36,31 (2015): 2087-2096. doi: https://doi.org/10.1093/eurheartj/ehv188
Kamperidis V, van Rosendael PJ, Katsanos S, van der Kley F, Regeer M, Al Amri I, Sianos G, Marsan NA, Delgado V, Bax JJ. Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data. Eur Heart J. 2015 Aug 14;36(31):2087-2096. doi: 10.1093/eurheartj/ehv188. Epub 2015 Jun 01. PMID: 26033985.
Copy Download .nbib Format: NLM
Comparative Genomics of Peroxisome Biogenesis Proteins: Making Sense of the PEX Proteins.

Frontiers in cell and developmental biology

Jansen RLM, Santana-Molina C, van den Noort M, Devos DP, van der Klei IJ.
PMID: 34095119
Front Cell Dev Biol. 2021 May 20;9:654163. doi: 10.3389/fcell.2021.654163. eCollection 2021.

PEX genes encode proteins involved in peroxisome biogenesis and proliferation. Using a comparative genomics approach, we clarify the evolutionary relationships between the 37 known PEX proteins in a representative set of eukaryotes, including all common model organisms, pathogenic unicellular...

Cite
Jansen RLM, Santana-Molina C, van den Noort M, et al. Comparative Genomics of Peroxisome Biogenesis Proteins: Making Sense of the PEX Proteins. Front Cell Dev Biol. 2021;9:654163doi: 10.3389/fcell.2021.654163.
Jansen, R. L. M., Santana-Molina, C., van den Noort, M., Devos, D. P., & van der Klei, I. J. (2021). Comparative Genomics of Peroxisome Biogenesis Proteins: Making Sense of the PEX Proteins. Frontiers in cell and developmental biology, 9654163. https://doi.org/10.3389/fcell.2021.654163
Jansen, Renate L M, et al. "Comparative Genomics of Peroxisome Biogenesis Proteins: Making Sense of the PEX Proteins." Frontiers in cell and developmental biology vol. 9 (2021): 654163. doi: https://doi.org/10.3389/fcell.2021.654163
Jansen RLM, Santana-Molina C, van den Noort M, Devos DP, van der Klei IJ. Comparative Genomics of Peroxisome Biogenesis Proteins: Making Sense of the PEX Proteins. Front Cell Dev Biol. 2021 May 20;9:654163. doi: 10.3389/fcell.2021.654163. eCollection 2021. PMID: 34095119; PMCID: PMC8172628.
Copy Download .nbib Format: NLM
Unacylated ghrelin binds heparan-sulfate proteoglycans which modulate its function.

Journal of molecular endocrinology

Delhanty PJD, Huisman M, Prins K, Steenbergen C, Mies R, Neggers SJCMM, van der Lely AJ, Visser JA.
PMID: 33263557
J Mol Endocrinol. 2021 Feb;66(2):83-96. doi: 10.1530/JME-20-0286.

Acylated ghrelin (AG) is a gut-derived peptide with growth hormone secretagogue (GHS), orexigenic and other physiological activities mediated by GHS receptor-1a (GHSR). Ghrelin occurs in unacylated form (UAG) with activities opposing AG, although its mechanism of action is unknown....

Cite
Delhanty PJD, Huisman M, Prins K, et al. Unacylated ghrelin binds heparan-sulfate proteoglycans which modulate its function. J Mol Endocrinol. 2021;66(2):83-96doi: 10.1530/JME-20-0286.
Delhanty, P. J. D., Huisman, M., Prins, K., Steenbergen, C., Mies, R., Neggers, S. J. C. M. M., van der Lely, A. J., & Visser, J. A. (2021). Unacylated ghrelin binds heparan-sulfate proteoglycans which modulate its function. Journal of molecular endocrinology, 66(2), 83-96. https://doi.org/10.1530/JME-20-0286
Delhanty, Patric J D, et al. "Unacylated ghrelin binds heparan-sulfate proteoglycans which modulate its function." Journal of molecular endocrinology vol. 66,2 (2021): 83-96. doi: https://doi.org/10.1530/JME-20-0286
Delhanty PJD, Huisman M, Prins K, Steenbergen C, Mies R, Neggers SJCMM, van der Lely AJ, Visser JA. Unacylated ghrelin binds heparan-sulfate proteoglycans which modulate its function. J Mol Endocrinol. 2021 Feb;66(2):83-96. doi: 10.1530/JME-20-0286. PMID: 33263557.
Copy Download .nbib Format: NLM
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly.

Endocrine connections

Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL.
PMID: 33434154
Endocr Connect. 2020 Dec;9(12):1178-1190. doi: 10.1530/EC-20-0361.

Pasireotide, a multireceptor-targeted somatostatin analog with highest affinity for somatostatin receptor subtype (SST) 5, has demonstrated superior efficacy over the SST2-preferential somatostatin analogs octreotide and lanreotide. The safety profile is similar to those of octreotide and lanreotide, except for...

Cite
Gadelha MR, Gu F, Bronstein MD, et al. Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect. 2020;9(12):1178-1190doi: 10.1530/EC-20-0361.
Gadelha, M. R., Gu, F., Bronstein, M. D., Brue, T. C., Fleseriu, M., Shimon, I., van der Lely, A. J., Ravichandran, S., Kandra, A., Pedroncelli, A. M., & Colao, A. A. L. (2020). Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocrine connections, 9(12), 1178-1190. https://doi.org/10.1530/EC-20-0361
Gadelha, Mônica R, et al. "Risk factors and management of pasireotide-associated hyperglycemia in acromegaly." Endocrine connections vol. 9,12 (2020): 1178-1190. doi: https://doi.org/10.1530/EC-20-0361
Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL. Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect. 2020 Dec;9(12):1178-1190. doi: 10.1530/EC-20-0361. PMID: 33434154; PMCID: PMC7774766.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries